Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Next Previous
Trial Profile

A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durlobactam/sulbactam (Primary) ; Colistin; Imipenem/cilastatin
  • Indications Acinetobacter infections; Bacteraemia; Nosocomial pneumonia; Postoperative infections; Urinary tract infections; Ventilator associated pneumonia; Wound infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ATTACK
  • Sponsors Entasis Therapeutics; ZAI Lab

Most Recent Events

  • 20 May 2024 According to a ZAI Lab media release, China's National Medical Products Administration (NMPA) has approved company's New Drug Application (NDA) for XACDURO (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.
  • 27 Feb 2024 According to a ZAI Lab media release, NMPA NDA approval for Sulbactam-durlobactam in infections caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in China expected in 2024.
  • 11 Oct 2023 According to an Innoviva media release, new data from this trial will be presented at IDWeek 2023, October 11-15, held in Boston, MA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top